United States Provides $1.5 Million in Tuberculosis Preventive Treatment to Indonesia

JAKARTA – The United States Agency for International Development (USAID) has announced it will provide tuberculosis (TB) preventive treatments (TPT) to 145,070 people in Indonesia, valued at $1,523,235—a key step in expediting preventive treatment access across the country and combating the spread of TB. To advance the prevention of TB globally, the United States, through the President’s Emergency Plan for AIDS Relief (PEPFAR), in collaboration with the Stop TB Partnership’s Global Drug Facility, worked to secure a 30 percent price reduction for the shortened TB prevention regimen—3HP—during the 2023 United Nations General Assembly High-Level Week in September.  As part of this effort, USAID launched a donation program for its TB priority countries to apply for these drugs.

Through this program, Indonesia is one of 11 countries receiving TB preventive treatments as part of USAID’s commitment to expand global TB prevention and end TB.  Indonesia has the second-highest TB burden in the world, with an estimated 1,060,000 new cases and 134,000 deaths each year.  USAID will work with the Ministry of Health to distribute these life-saving treatments.

“The United States, through USAID, is proud to partner with the Government of Indonesia to improve health outcomes for the Indonesian people, including for tuberculosis,” said USAID Indonesia Mission Director Jeff Cohen.  “Our donation of TB preventive treatments demonstrates the depth of our partnership, as we continue working together to save lives and eliminate TB in Indonesia by 2030.”

3HP is a short-course TPT regimen which is endorsed by the WHO.  It combines high dose Isoniazid (H) and high dose rifapentine (P) once weekly for three months.  Shorter TPT regimens like 3HP are linked to higher adherence, completion rates, and outcomes. Taking these regimens increases the likelihood of completing the course by up to three times, leading to better results and more lives saved.  Shorter regimens reduce the burden on healthcare systems and improve resource allocation; they are cost-effective when considering reduced healthcare utilization and improved patient outcomes.  The 3HP donation will significantly advance the USAID’s Global TB Strategy (2023-2030) and the attainment of its 90-90-90+prevention results framework, namely initiating 30 million contacts on TPT in 24 USAID TB priority countries by 2030.

As the world’s largest bilateral donor leading the fight to end TB, USAID has provided $4.7 billion in assistance to combat TB globally since 2000, and together with our partners, saved more than 75 million lives to date.

For more information, visit USAID INDONESIA or contact USAID Outreach and Communications Lead Swiny Andina at +62 (21) 5083-1000 or sandina@usaid.gov.